Consun Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 6/6
Consun Pharmaceutical Group has a total shareholder equity of CN¥4.0B and total debt of CN¥507.7M, which brings its debt-to-equity ratio to 12.7%. Its total assets and total liabilities are CN¥5.5B and CN¥1.5B respectively. Consun Pharmaceutical Group's EBIT is CN¥882.9M making its interest coverage ratio -16.8. It has cash and short-term investments of CN¥3.6B.
Key information
12.7%
Debt to equity ratio
CN¥507.70m
Debt
| Interest coverage ratio | -16.8x |
| Cash | CN¥3.58b |
| Equity | CN¥3.99b |
| Total liabilities | CN¥1.50b |
| Total assets | CN¥5.49b |
Recent financial health updates
These 4 Measures Indicate That Consun Pharmaceutical Group (HKG:1681) Is Using Debt Safely
Nov 27
Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
Jun 12Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
May 04Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly
Apr 21Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly
Dec 18Recent updates
These 4 Measures Indicate That Consun Pharmaceutical Group (HKG:1681) Is Using Debt Safely
Nov 27Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story
Oct 02Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors
Sep 26Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
Jun 12Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30
May 12Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30
Jun 01Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
May 04Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20
Apr 28Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20
Apr 07Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10
Aug 26Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly
Apr 21Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?
Mar 17Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative
Feb 19How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 29Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?
Jan 08
Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly
Dec 18Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?
Nov 18Financial Position Analysis
Short Term Liabilities: 1681's short term assets (CN¥4.2B) exceed its short term liabilities (CN¥1.4B).
Long Term Liabilities: 1681's short term assets (CN¥4.2B) exceed its long term liabilities (CN¥112.5M).
Debt to Equity History and Analysis
Debt Level: 1681 has more cash than its total debt.
Reducing Debt: 1681's debt to equity ratio has reduced from 27.7% to 12.7% over the past 5 years.
Debt Coverage: 1681's debt is well covered by operating cash flow (180.3%).
Interest Coverage: 1681 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 16:54 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Consun Pharmaceutical Group Limited is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fangqi Dai | China Merchants Securities (HK) Co., Ltd |
| null null | CMB International Securities Limited |
| Trina Chen | Credit Suisse |